Affiliation:
1. Liaoning Inspection, Examination & Certification Centre, Shenyang110036, China
2. Liaoning University of Traditional Chinese Medicine, Shenyang110847, China
Abstract
Background:
Erigeron breviscapus (Vant.) Hand-Mazz. is a plant species in the Compositae family.
More than ten types of compounds-such as flavonoids, caffeinate esters, and volatile oils-have been identified
in Erigeron breviscapus; however, it remains unknown as to which compounds are associated with clinical efficacy.
In recent years, flavonoids and phenolic acids have been considered as the main effective components of
Erigeron breviscapus. The metabolism and mechanisms of these compounds in vivo have been extensively
studied to improve our understanding of the drug.
Methods:
In the present review, we summarize the relationships among these compounds, their metabolites,
and their pharmacodynamics. Many methods have been implemented to improve the separation and bioavailability
of these compounds from Erigeron breviscapus.
Results:
In China, Erigeron breviscapus has been used for many years. In recent years, through the study of its
metabolism and the mechanisms of its effective components, the effects of Erigeron breviscapus in the treatment
of various diseases have been extensively studied. Findings have indicated that Erigeron breviscapus improves
cardiovascular and cerebrovascular function and that one of its ingredients, scutellarin, has potential value
in the treatment of Alzheimer's disease, cancer, diabetic vascular complications, and other conditions. In addition,
phenolic acid compounds and their metabolites also play an important role in anti-oxidation, anti-inflammation,
and improving blood lipids.
Conclusion:
Erigeron breviscapus plays an important role in the prevention and treatment of cardiovascular/
cerebrovascular diseases, neuroprotection, and cancer through many different mechanisms of action. Further
investigation of its efficacious components and metabolites may provide more possibilities for the clinical application
of traditional Chinese medicine and the development of novel drugs.
Funder
Liaoning Natural Science Foundation Coctoral Research Initiation
Publisher
Bentham Science Publishers Ltd.
Subject
Clinical Biochemistry,Pharmacology
Reference156 articles.
1. Guo X.; Lin S.; Wu L.M.; Tian X.H.;
Progress in the study of chemical constituents and pharmacological effects of Erigeron breviscapus.
J.
Zhongchengyao 2009,41,393-402
2. Yue J.M.; Lin Z.W.; Sun H.D.; A new caffeoyl conjugate from Erigeron breviscapus. Chin Chem Lett 1997,8,225-228
3. Zhang W.D.; Ha T.B.; Chen W.S.; Kong D.Y.; Li H.T.; Wang Y.H.; Fouraste L.; Structure and activity of phenolic acids in Erigeron breviscapus. Chung Kuo Yao Hsueh Tsa Chih 2002,37,579-582
4. Li J.; Yu D.Q.; Study on chemical constituents of breviscapus. Chin J Chin Mater Med 2011,36,1458-1462
5. Wang Y.F.; Hu L.M.; Liu Y.N.; Pan X.P.; Pan G.X.; Chang Y.X.; Gao X.M.; A rapid method for qualitative and quantitative analysis of major constituents in Dengzhanxixin injection by LC-DAD-ESI-MSn. Chromatographia 2010,71,845-853